mogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy primarily of the right ventricle characterized through fibrofatty replacement of cardiomyocytes. The genetic etiology in ARVC patients is most commonly caused by dominant inheritance and high genetic heterogeneity. Though histological examinations of ARVC-affected human myocardium reveals fibrolipomatous replacement, the molecular mechanisms leading to loss of cardiomyocytes are largely unknown. We therefore analyzed the transcriptomes of six ARVC hearts and compared our findings to six nonfailing donor hearts (NF). To characterize the ARVC-specific transcriptome, we compared our findings to samples from seven patients with idiopathic dilated cardiomyopathy (DCM). The myocardial DCM and ARVC samples were prepared from hearts explanted during an orthotopic heart transplantation representing myocardium from end-stage heart failure patients (NYHA IV). From each heart, left (LV) and right ventricular (RV) myocardial samples were analyzed by Affymetrix HG-U133 Plus 2.0 arrays, adding up to six sample groups. Unsupervised cluster analyses of the groups revealed a clear separation of NF and cardiomyopathy samples. However, in contrast to the other samples, the analyses revealed no distinct expression pattern in LV and RV of myocardial ARVC samples. We further identified differentially expressed transcripts using t-tests and found transcripts separating diseased and NF ventricular myocardium. Of note, in failing myocardium only ϳ15-16% of the genes are commonly regulated compared with NF samples. In addition both cardiomyopathies are clearly distinct on the transcriptome level. Comparison of the expression patterns between the failing RV and LV using a paired t-test revealed a lack of major differences between LV and RV gene expression in ARVC hearts. Our study is the first analysis of specific ARVC-related RV and LV gene expression patterns in terminal failing human hearts.
affected (6, 42, 51, 74) . The cellular fibrofatty replacement within the ventricular walls results in right ventricular enlargement, life-threatening arrhythmias, and sudden cardiac death (6, 42, 74) . ARVC is a familial disease with recessive and most commonly dominant inheritance (3, 26) .
In a number of genetic studies at least 11 chromosomal loci for ARVC and some of the causal genes have been identified, reflecting high genetic heterogeneity (17, 28, 40, 53, 63) . Five genes (DSP, PKP2, DSG2, DSC2, and JUP) code for the desmosomal proteins desmoplakin, plakophilin-2, desmoglein-2, desmocollin-2, and plakoglobin, respectively (25, 28, 41, 44, 50, 64, 70, 71) . The remaining genes are the cardiac ryanodine receptor 2 (RYR2), transforming growth factor beta-3 (TGFB3), transmembrane protein 43 (TMEM43) (7, 45, 76) , desmin (DES) (35) , and titin (TTN) (73) .
Histological examinations of ARVC affected human myocardium (13) revealed that fibrolipomatous replacement is accompanied with metabolic, ultrastructural, inflammatory, or apoptotic injuries (5, 4) . Recently, myocyte necrosis was postulated as a key initiator of myocardial dystrophy in DSG2-related ARVC (55) . However, up to now the molecular mechanisms leading to myocardial fatty tissue infiltration are largely unknown.
Desmosomes are cell junctions securing the structural and functional integrity of cardiac tissue. They are robust structures that are primarily abundant in tissues that are subject to strong contractile stress or abrasive forces (22, 52, 58) . Together with adherens junctions and gap junctions they are located at the intercalated discs, the main site of myocyte interconnection (69, 77) . In the heart, the desmosomal proteins plakoglobin (PG), plakophilin 2 (PKP2), and desmoplakin (DSP) connect DES intermediate filaments to the desmosomal cadherins desmoglein 2 (DSG2) and desmocollin 2 (DSC2). Electron microscopy of endomyocardial biopsies of ARVC patients revealed remodeling of intercalated discs with widening of intercellular space and abnormal desmosomes (5) .
Desmosomal proteins are also involved in signal transduction, which might result in changes of the myocardial gene expression pattern (23) . We therefore analyzed the transcriptome of myocardial ARVC samples and compared our findings to nonfailing (NF) donor hearts that could not be transplanted for technical reasons and to samples from patients with idiopathic dilated cardiomyopathy (DCM).
DCM is a major cause of morbidity and mortality among cardiovascular diseases and a leading indication for heart transplantation (47) . DCM is defined by dilatation and systolic impairment of the left or both ventricles commonly presenting with signs and symptoms of heart failure (20) . In up to 48% of the cases DCM is a familial disease with predominantly autosomal inheritance. However, only for a small number of patients the genetic determinants have been characterized (10, 16, 46) . Besides mutations in cytoskeletal and sarcomeric protein genes (10) , recently mutations in genes coding for desmosomal proteins have also been associated with DCM (21) . Additionally, several nongenetic causes of DCM like myocarditis, nutritional deficiencies, or endocrine dysfunction are known (20) .
In contrast to DCM RV disease needs to be identified for clinical diagnosis of ARVC. Although biventricular, or in some cases even LV, disease predominance is observed (51, 66) . It is discussed that nonclassical subtypes of ARVC are commonly misattributed to DCM (65, 66) . In contrast to DCM ARVC patients may be at risk of SCD even when the ventricular function is preserved (14, 26, 49) .
In this study gene expression data of idiopathic DCM was compared with the transcriptome of end-stage ARVC hearts for the identification of disease specific transcripts.
MATERIAL AND METHODS

Patient Population
We analyzed paired myocardial samples taken from the LV and RV of 13 terminal cardiomyopathy patients from our heart-transplantation program. Of these, six had ARVC, according to novel task force criteria (63) , whereas seven had idiopathic DCM, without signs of familial etiology or coronary artery disease, respectively. The myocardial samples were prepared from hearts explanted during orthotopic heart transplantation representing myocardium from end-stage heart failure patients (NYHA IV). The study was approved by the institutional ethics committee, and all patients provided written informed consent with the use of tissue samples. According to echo examinations and hemodynamic data used for transplant listing (Table 1 , norm values) (11, 40, 48) the ARVC patients had significantly different values for LV-EF, LVEDD, CVP, PAP, PVR, and PAWP compared with DCM patients. All hemodynamic and echo data revealed RV failure in the ARVC patients and LV remodeling in the DCM group. Patients with ARVC or DCM had no history of cardiac infarction and/or coronary stenosis, respectively.
Furthermore, we compared the data with six NF donor hearts, which could not be transplanted for technical reasons and were removed from the donor for cardiac valve grafting. Samples were matched according to age and sex. For clinical data see Table 2 . Myocardial samples were collected, and RNA isolated as described before (36) . In brief, the myocardium was obtained from patients undergoing cardiac transplantation or from NF hearts and prepared according to a standardized operating procedure: The transmural LV and RV tissue samples were collected from the ventricular free walls, immediately frozen in liquid nitrogen (cold ischemia time Ͻ30 min), and stored at Ϫ80°C until extraction of the RNA. The isolated samples were macroscopically free of fibrotic scares and fatty infiltrations. Total RNA was extracted from ϳ30 mg myocardial tissue using a commercial RNA-isolation kit (RNeasy kit and RNase-free DNase Set; Qiagen, Hilden, Germany). The average yield of RNA extraction was 0.2 g/mg wet weight tissue. Quantification of RNA was done with a spectrophotometer at 260 nm.
Array Hybridization
Total RNA was quantified by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE), and quality was assessed by a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). All samples displayed an RNA integrity number Ͼ8.0. Doublestranded cDNA synthesis and in vitro transcription (IVT) were carried out according to Affymetrix protocols. In brief, 1 g of total RNA was reverse transcribed with SuperScript II and T7-Oligo(dT) 24 Promotor Primer for 1 h at 42°C, followed by 2 h at 16°C RNase H-mediated second-strand cDNA synthesis. After sample clean-up the cDNA served as a template for subsequent IVT. The IVT reaction was carried out in the presence of T7 RNA polymerase and a biotinylated nucleotide analog/ribonucleotide mix for complementary RNA (cRNA) amplification and biotin labeling for 16 h at 37°C.
The quality of cRNA was assessed by a 2100 Bioanalyzer. Biotinylated cRNA was cleaned up, and 15 g were fragmented by metal/ heat induced fragmentation. The fragmented cRNA was hybridized against GeneChip Human Genome U133 Plus 2.0 in a Affymetrix GeneChip Hybridization Oven for 16 h at 45°C and 60 rpm. The Affymetrix HG-U133 Plus 2.0 arrays provide coverage of the whole human genome with 47,000 transcripts and variants of 38,500 characterized human genes and 54,000 probe-sets.
Each microarray was washed and stained with streptavidin-phycoerythrin using Affymetrix GeneChip Fluidics Station 450 and then scanned with Affymetrix Scanner 3000 according to the technical manual of Affymetrix.
Data Analysis and Quality Control
Fluorescence intensities of scanned images (Affymetrix) were corrected for background noise, normalized, and evaluated using the Affymetrix Microarray Analysis Suite (MAS 5.0) software. For normalization, all probes were globally scaled to a target signal of 100 to ensure data comparability across all arrays used in this study. For reproducibility, these files have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE29819 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accϭGSE29819). For quality control, quantitative real-time PCR of selected genes was performed using Taqman technology as previously described (61) and compared with the corresponding microarray expression levels.
Further statistical analysis was performed with Expressionist software (Genedata, Basel, Switzerland). We analyzed prior to the 2 Disease classification according to task force criteria (63) . 3 Nomenclature of sequence and amino acid changes according the specifications of the Human Genome Variation Society; all variants were heterozygous. 4 Amino acid substitution.
t-tests the rate of false positives using a balanced permutation approach (24) as a standard procedure within the Expressionist software (62) . Clinical data in Table 2 were analyzed by unpaired student t-tests using GraphPad Prism v5.04 for Windows (GraphPad Software, San Diego, CA).
RESULTS
Cluster Analysis
Principal component analysis of the six sample groups. The unsupervised principal component analysis (PCA) of the six sample groups investigated in this study is shown in Fig. 2A . The data reveal a clear separation of NF and cardiomyopathy samples on principal component 1, accounting for the highest variance within the datasets. Moreover, the data are also separated along the axis of component 2, indicating that the NF samples from RV and LV myocardium can be distinguished by their transcriptome.
We also observed separation of the transcriptome pattern between RV and LV myocardial samples from DCM patients. Of note, the transcriptome of LV and RV myocardial ARVC samples does not show distinction by PCA. Apparently, the expression profiles of the LV ARVC samples form a common cluster with the RV samples. Additionally we found a common cluster of RV DCM samples and the ARVC samples.
Hierarchical clustering of all samples. NF samples could also be separated from diseased ones by the application of an unsupervised hierarchical clustering (HC) algorithm (Fig. 2B) . Additionally, most of the myocardial DCM samples were grouped in two separate clusters distinct from RV and LV ARVC samples. The samples of all but one ARVC patients were found within one branch.
Interestingly, RV and LV myocardium of ARVC hearts of all but one ARVC patient could not be separated by HC, whereas most of the LV and RV samples derived from seven DCM hearts were found in separate clusters. The LV and RV of one ARVC sample clustered together with three RV DCM samples. Furthermore, all but one LV DCM sample clustered together, whereas two clusters were found for the RV. Of note, LV and RV samples of those patients with desmosomal mutations (P03 and P04) were localized in a common cluster.
PCA of the ARVC LV and RV samples. In Fig. 3 , two different views to the same PCA of the ARVC LV and RV samples are shown. Detailed labeling of the samples reveals a common cluster for LV and RV samples of patients with desmosomal gene mutations. The other samples including those from the patient with the desmin mutation p.N116S do not form a common cluster. Of note, samples from LV and RV of each patient cluster together.
Statistical Testing
We further identified differentially expressed transcripts using stringent t-tests with a P value cutoff of 0.001 (P Ͻ 0.001) and a fold-change (FC) threshold of Ն1.6. In accordance with our cluster analysis, we identified transcripts differentially expressed between diseased and NF ventricular myocardium. Moreover, we analyzed transcripts differentially Interestingly, of the heart failure associated transcripts only 16% were commonly regulated in LV and 15% in RV myocardium of both cardiomyopathies, whereas vice versa most of these mRNAs are typically found to be regulated either in DCM or in ARVC myocardium. Both cardiomyopathies are therefore clearly distinct on the transcriptome level.
We generated a list of transcripts specific for the LV and RV of ARVC samples by excluding those transcripts expressed in both forms of cardiomyopathy. The top regulated genes found in LV ARVC samples are listed in Table 3 . The complete list is shown in Supplementary Table S1. 1 Accordingly, Table 4 presents the 30 most regulated transcripts of the RV ARVC samples, (see Supplementary Table S2 for the complete list). There were also several genes found to be commonly regulated between DCM and ARVC compared with NF myocardial samples. All significantly regulated transcripts of the LV and RV are presented in Supplementary Tables S3 and S4 , respectively.
The regulation of selected genes was confirmed by real-time RT-PCR. The genes, their FC in gene expression, and the P values are listed in Table 5 .
Comparison of Failing Ventricles
We compared the expression patterns between failing RV and LV using paired t-tests under the same conditions as applied previously (P Ͻ 0.001, FC Ն 1.6). In accordance to the PCA ( Fig. 2A) we could not identify a single transcript to be differentially expressed between the RV and LV of ARVC hearts under these conditions. However, under relaxed conditions (P Ͻ 0.01; FC Ն 1.3) we identified 13 transcripts separating RV and LV ARVC myocardium. These are listed in Table 6 . The lack of major differences between LV and RV gene expression in ARVC hearts is also illustrated in the volcano plot (Fig. 5) .
DISCUSSION
ARVC is regarded as an inherited cardiomyopathy with heterogeneous etiology (19) , which is preferentially caused by mutations in genes encoding desmosomal proteins. In addition, TMEM43, coding for a protein with unknown function located in the inner nuclear lamina (8) or the plasma membrane (13), 1 The online version of this article contains supplemental material. was recently identified as a novel ARVC-causing gene. We included six ARVC patients in our study who were previously genetically characterized by sequencing of DES and the desmosomal genes DSG2, DSC2, PKP2, DSP, and JUP (35) . We found in three of these patients sequence variants that are related to the disease (see Table 2 for details).
Proteins involved in the cell contacts of the intercalated discs were reported to be involved in regulation of gene expression (23) . We therefore hypothesized that the transcriptome of the ARVC myocardium might display a characteristic gene expression pattern compared with DCM and control hearts.
Cardiomyopathies were claimed to be associated with typical alterations of the gene expression pattern compared with nonfailing myocardium (34, 37, 72) . We analyzed the expression patterns of a matched cohort of idiopathic DCM and corresponding ARVC patients by microarray technology, to identify which of the transcripts were differentially regulated in these cardiomyopathies.
Up to now microarray data from the LV and RV of human ARVC hearts were not available to the best of our knowledge. Therefore, we analyzed RV and LV myocardial ARVC samples and compared the gene expression patterns with nonfailing controls and matched DCM hearts, respectively. Our data indicate that ARVC is a cardiomyopathy, which is not restricted to the RV. Surprisingly, the PCA reveals that RV and LV gene expression patterns of ARVC hearts are rather similar but clearly distinguishable from NF control myocardium or the LV of DCM hearts, respectively. It is remarkable that none of the desmosomal genes, which carry mutations in ARVC patients, are differentially expressed in the RV of myocardial ARVC samples. Only in the LV ARVC myocardium DSC2 and PKP2 are regulated compared with NF.
Gene Expression Analysis Reveals Biventricular Cardiomyopathy in ARVC
The gene expression data presented in our study reveal LV involvement in end-stage ARVC patients. Surprisingly, although the clinical phenotype of the RV is different we found hardly any difference in the gene expression pattern between the two ventricles in ARVC patients on the transcriptome level. The low number of 13 differently regulated transcripts between RV and LV ARVC myocardium under relaxed statistical conditions (Table 6) indicates that the LV is much more involved in ARVC pathogenesis than previously anticipated.
Furthermore, the PCA reveals that the specific expression of ARVC-related transcripts leads to segregation of LV DCM and LV NF myocardium. Of note, we found different transcripts between LV and RV myocardial samples from NF hearts. Additionally, NF myocardium is clearly distinguishable by transcriptome analysis from the failing ventricles analyzed in our study. Interestingly, the PCA of the ARVC subgroup revealed a common cluster for LV and RV samples derived from those patients with desmosomal gene mutations, which suggests common transcriptional changes in this cohort.
Since there are clear differences in gene expression between ARVC and NF some of the top regulated genes characteristic for ARVC are discussed. 
Regulated Genes in the RV of ARVC
One of the genes much stronger expressed in RV samples of ARVC patients compared with NF myocardial samples is coding for the Pleckstrin homology-like domain, family A, member 1 (PHLDA1), also known as T-cell death-associated gene 51 (TDAG51). Overexpression of this protein could be shown to be associated with significant changes in cell morphology, decreased cell adhesion, and promoted detachmentmediated programmed cell death (PCD) in endothelial cells (29) . PCD in ARVC tissue could lead to the loss of adhesive properties of myocytes and to their shedding into the circulation, a possible mechanism for the loss of myocytes in the RV of ARVC patients.
Another gene with a higher expression level in the RV of ARVC patients compared with RV samples from NF myocardium is Secreted frizzled-related protein 1 (SFRP1). SFRP1 antagonizes the Wnt/Frizzled pathway by binding to Wnt and preventing it from accessing its cell-surface receptor Frizzled (17, 18, 31) . It is supposed to inhibit the canonical as well as the noncanonical Wnt signaling (4, 17) . The involvement in noncanonical Wnt signaling is characterized by the inhibition of Ser-9 phosphorylation of GSK3␤ by overexpression of SFRP1 in cardiomyocytes (4). As inhibition of GSK3␤ for example by phosphorylation is supposed to be cardio-protective, antagonizing the antiapoptotic mechanism might contribute to the clinical presentation of ARVC (4, 53). Transcription of the gene coding for Actin-binding Rhoactivating protein (ABRA) also called Striated muscle activator of Rho signaling (STARS) is 6.5-fold less strongly expressed in the RV of ARVC patients compared with RV from NF controls. ABRA is a muscle-specific actin-binding protein localized in the I-band and the M-line of the sarcomere (1) . It can activate SRF-mediated transcription and is overexpressed in mouse models of cardiac hypertrophy and in myopathic human hearts (38, 39) . Cardiac overexpression of ABRA was shown to be linked to increased expression of SRF-dependent fetal cardiac genes and sensitization of the heart to biomechanical stress (39) . As ABRA seems to act as a modulator of the cardiac stress response the downregulation of ABRA mRNA in ARVC RV could be linked to a disturbed stress response in the RV of ARVC patients. Since ARVC is claimed to be a disease of the cardiac desmosome the disruption of the cardiac stress response in ARVC appears feasible.
Regulated Genes in the LV of ARVC
Some of the genes shown to be specifically downregulated in ARVC (Table 2) in our LV samples, like the inflammationassociated enzyme phospholipase A2 type IIA (PLA2G2A), the K ϩ channel-interacting protein (KCNIP2) with a broad physiological role in cardiac electrophysiology, and the Serine protease inhibitor member 3 of clade A (SERPINA3), were previously shown to be associated with different forms of heart failure (56, 60, 72, 75, 81) .
The mRNA of Spectrin beta nonerythrocytic 1 (SPTBN1) was found to be upregulated in LV of ARVC patients. Spectrin is a tetrameric cytoskeletal protein, which was claimed to be essential for the determination of the cell shape, and is involved in the resilience of membranes upon mechanical stress (27) . The spectrin ␤-subunits like SPTNB1 contain most of the spectrin binding activity (27) .
Among the upregulated genes we could not find Ankyrin repeat domain 1 (ANKRD1, also called CARP), a gene previously found to be upregulated in the LV of ARVC patients compared with NF (80) . As the gene was also found to be upregulated in DCM and ischemic cardiomyopathic hearts (82), its regulation is not specific for ARVC. However, in our study we were not able to find differential expression of ANKRD1 compared with NF among the genes regulated in DCM and/or ARVC neither in LV nor in RV. Thus, the thesis that augmented CARP expression can be estimated as a common molecular event in failing hearts (80) cannot be confirmed by our study.
No Regulation of Genes Coding for Proteins Linked to Fibrogenesis or Adipogenesis
Although ARVC is claimed to be associated with fibrofatty replacement of cardiomyocytes, surprisingly neither fibrosis- . It can be seen that the dark gray area contains no transcripts, which indicates that the differences between the sample groups are low compared with the tests in Fig. 2 . Therefore, the test parameters were relaxed, as shown by the light gray area (P Ͻ 0.01, FC Ն 1.3). We found 13 transcripts to be significantly differentially expressed under these conditions. The complete list can be seen in 
No Regulation of Genes Coding for Desmosomal Proteins in the RV
Although ARVC was shown to be associated with mutations in genes coding for desmosomal proteins (35) no transcriptional regulation of these genes was observed in the RV of ARVC patients in our study. Surprisingly, in the LV of ARVC patients the gene expression of PKP2 was shown to be 1.75-fold upregulated and expression of DSC2 1.62-fold downregulated (Supplementary Table S1 ). This reveals that in the less affected LV the regulation of the genes coding for these desmosomal proteins might be involved in the pathogenesis of ARVC.
Genes Commonly Regulated in DCM and ARVC
One of the genes upregulated in the LV of failing myocardial samples is the nucleosome assembly protein 1-like 3 (NAP1L3). NAP1L3 is a member of the NAP1L family, a group of nucleosome assembly proteins (79) . We speculate that similar to NAP-1 NAP1L3 is involved in transcriptional regulation (12, 30, 33, 68) . Common upregulation of NAP1L3 in LV ARVC and DCM could be linked to the obvious transcriptional changes compared with NF.
Another gene commonly upregulated in the LV of ARVC and DCM samples is coding for leukemia inhibitory factor receptor (LIFR). After binding to its ligand cardiotrophin 1 the signal transducer heterodimer consisting of LIFR/glycoprotein 130 (gp130) triggers the best-characterized survival pathway in cardiac tissue (54, 57, 67) . Upregulation of this receptor could inhibit death stimuli in the failing myocardium.
Interestingly, the gene coding for chemokine cc motif ligand 2 (CCL2) is commonly downregulated in the LV and RV of ARVC and DCM samples. This is quite remarkable as elevated levels of inflammatory cytokines are known to be associated with chronic heart failure (2, 15) .
Furthermore, the gene coding for phosphatidylinositol 3 kinase regulatory subunit 1 (PIK3R1) is commonly upregulated in the LV and RV of DCM and ARVC patients compared with NF. As phosphatidylinositol 3 kinase was shown to be critical for myofiber maturation and Z-disc alignment expression changes of its regulatory subunit PIK3R1 might be of interest as a common hypertrophy regulator in heart failure (78) .
Some of the genes commonly regulated in ARVC and DCM (Supplementary Tables S3 and S4) are also found as genes specifically regulated in ARVC in Tables 3 and 4 (and Supplementary Tables S1 and S2) , respectively. This is due to the presence of several probe sets representing different splice forms of the same gene (e.g., for PHLDA1 and SPTBN1), which suggests differential splice-form expression of these genes between DCM and ARVC.
Limitations of the Study
In our study we used myocardial samples from end-stage heart failure patients explanted during orthotopic heart transplantation for genomics analysis. Thus, the gene expression patterns shown in our manuscript reflect the transcriptome of end-stage ARVC. We do not know, whether the transcripts identified will also be regulated in less severe stages of the disease.
Although the analysis of gene expression using Affymetrix HG-U133 Plus 2.0 arrays is highly standardized and a powerful technology, we do not present data on the protein level. In addition, it was previously found, that next generation sequencing technologies will provide also data on rather low abundant mRNAs (43) .
Nevertheless, this analysis offers further insight into the disease mechanisms of ARVC and might probably reveal further candidate genes relevant for molecular genetics of ARVC.
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